Cargando…

Novel Bruton’s tyrosine kinase inhibitor TAS5315 suppresses the progression of inflammation and joint destruction in rodent collagen-induced arthritis

Rheumatoid arthritis is an inflammatory autoimmune disease, characterized by autoantibody production, synovial inflammation, and joint destruction. Its pathogenesis is due to environmental factors and genetic backgrounds. Bruton’s tyrosine kinase is a cytoplasmic non-receptor tyrosine kinase, expres...

Descripción completa

Detalles Bibliográficos
Autores principales:	Akasaka, Daichi, Iguchi, Satoru, Kaneko, Ryusuke, Yoshiga, Yohei, Kajiwara, Daisuke, Nakachi, Yoshinori, Noma, Naruto, Tanaka, Kenji, Shimizu, Atsushi, Hosoi, Fumihito
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9949657/ https://www.ncbi.nlm.nih.gov/pubmed/36821545 http://dx.doi.org/10.1371/journal.pone.0282117

Ejemplares similares

Irreversible covalent Bruton’s tyrosine kinase inhibitor, TAS5315 versus placebo in rheumatoid arthritis patients with inadequate response to methotrexate: a randomised, double-blind, phase IIa trial
por: Takeuchi, Tsutomu, et al.
Publicado: (2023)

LasΔ5315 Effector Induces Extreme Starch Accumulation and Chlorosis as Ca. Liberibacter asiaticus Infection in Nicotiana benthamiana
por: Pitino, Marco, et al.
Publicado: (2018)

Correction: Peters et al. Benchmarking the ACEnano Toolbox for Characterisation of Nanoparticle Size and Concentration by Interlaboratory Comparison. Molecules 2021, 26, 5315
por: Peters, Ruud, et al.
Publicado: (2022)

Association Between Aldehyde dehydrogenase-2 Polymorphisms and Risk of Alzheimer's Disease and Parkinson's Disease: A Meta-Analysis Based on 5,315 Individuals
por: Chen, Jun, et al.
Publicado: (2019)

Shieldings: TAS
Publicado: (2004)

Shieldings: TAS
Publicado: (2004)

Prevention of Bone Destruction by Mechanical Loading Is Not Enhanced by the Bruton’s Tyrosine Kinase Inhibitor CC-292 in Myeloma Bone Disease
por: Ziouti, Fani, et al.
Publicado: (2021)

Bruton's Agammaglobulinemia and COVID-19
por: Hovey, Justin G, et al.
Publicado: (2020)

Assessment of five different guideline indication criteria for spirometry, including modified GOLD criteria, in order to detect COPD: data from 5,315 subjects in the PLATINO study
por: Luize, Ana P, et al.
Publicado: (2014)

Vanillin Activates Human Bitter Taste Receptors TAS2R14, TAS2R20, and TAS2R39
por: Morini, Gabriella, et al.
Publicado: (2021)

Tas chebal : jun chajp a'tel pajbil /
por: González Dillon, Mónica
Publicado: (2013)

Bruton's tyrosine kinase: oncotarget in myeloma
por: Tai, Yu-Tzu, et al.
Publicado: (2012)

Correction: Bruton's Agammaglobulinemia and COVID-19
por: Hovey, Justin G, et al.
Publicado: (2021)

Editorial: Targeting Bruton Tyrosine Kinase
por: Brunner, Cornelia, et al.
Publicado: (2022)

Targeting Bruton’s Tyrosine Kinase in CLL
por: Ahn, Inhye E., et al.
Publicado: (2021)

Therapeutic potential of TAS-115 via c-MET and PDGFRα signal inhibition for synovial sarcoma
por: Yamada, Shutaro, et al.
Publicado: (2017)

Energy Deposition in the Triplet and TAS Issues
por: Broggi, F
Publicado: (2008)

Implementation of TasP: challenges and opportunities
por: Lange, Joep
Publicado: (2014)

TAS-102 and the quest for predictive biomarkers
por: van der Velden, Daphne L, et al.
Publicado: (2017)

Regulatory Phosphorylation of Ikaros by Bruton's Tyrosine Kinase
por: Ma, Hong, et al.
Publicado: (2013)

Second-generation inhibitors of Bruton tyrosine kinase
por: Wu, Jingjing, et al.
Publicado: (2016)

Bruton’s Tyrosine Kinase Targeting in Multiple Myeloma
por: Von Suskil, Max, et al.
Publicado: (2021)

Bruton’s Tyrosine Kinase and Its Isoforms in Cancer
por: Wang, Xianhui, et al.
Publicado: (2021)

Bruton’s Tyrosine Kinase Inhibition in Multiple Sclerosis
por: Schneider, Raphael, et al.
Publicado: (2022)

Bruton tyrosine kinase inhibitors for multiple sclerosis
por: Krämer, Julia, et al.
Publicado: (2023)

Vegetative Skin Lesions in Patient with Bruton's Agammaglobulinemia
por: Fidanzi, Cristian, et al.
Publicado: (2023)

Cost-effectiveness of TAS-102 plus bevacizumab versus TAS-102 monotherapy in patients with metastatic colorectal cancer
por: Sugiura, Kiyoaki, et al.
Publicado: (2021)

Generation of Rodent Malaria Parasites with a High Mutation Rate by Destructing Proofreading Activity of DNA Polymerase δ
por: Honma, Hajime, et al.
Publicado: (2014)

Tunable Contact Types and Interfacial Electronic Properties in TaS(2)/MoS(2) and TaS(2)/WSe(2) Heterostructures
por: Zhu, Xiangjiu, et al.
Publicado: (2023)

Tas2R signaling enhances mouse neutrophil migration via a ROCK-dependent pathway
por: Kobayashi, Daichi, et al.
Publicado: (2022)

Members of Bitter Taste Receptor Cluster Tas2r143/Tas2r135/Tas2r126 Are Expressed in the Epithelium of Murine Airways and Other Non-gustatory Tissues
por: Liu, Shuya, et al.
Publicado: (2017)

Enhanced superconductivity in atomically thin TaS(2)
por: Navarro-Moratalla, Efrén, et al.
Publicado: (2016)

Raman Optical Activity of 1T-TaS(2)
por: Lacinska, Ewa M., et al.
Publicado: (2022)

Role of Bruton's Tyrosine Kinase in B Cell Development
por: Maas, Alex, et al.
Publicado: (2001)

Novel Bruton’s tyrosine kinase inhibitors currently in development
por: D’Cruz, Osmond J, et al.
Publicado: (2013)

Role of Bruton’s tyrosine kinase in B cells and malignancies
por: Pal Singh, Simar, et al.
Publicado: (2018)

Bruton’s Tyrosine Kinase Inhibition Promotes Myelin Repair
por: Martin, Elodie, et al.
Publicado: (2020)

Bruton’s Tyrosine Kinase Inhibition for the Treatment of Rheumatoid Arthritis
por: Arneson, Laura C, et al.
Publicado: (2021)

Targeting Bruton’s Tyrosine Kinase in Inflammatory and Autoimmune Pathologies
por: Neys, Stefan F. H., et al.
Publicado: (2021)

Editorial: New Insights on Bruton’s Tyrosine Kinase Inhibitors
por: Smith, C. I. Edvard, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_pcfb6fq42bkbn5ijj4fkosnl4l